Renin-angiotensin system blockade alone or combined with ETA receptor blockade: effects on the course of chronic kidney disease in 5/6 nephrectomized Ren-2 transgenic hypertensive rats

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F67985823%3A_____%2F17%3A00474019" target="_blank" >RIV/67985823:_____/17:00474019 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11120/17:43913090 RIV/00216208:11130/17:10359897 RIV/00216208:11310/17:10359897 RIV/00023001:_____/17:00060252 RIV/00216208:11110/17:10359897

Result on the web

<a href="http://dx.doi.org/10.1080/10641963.2016.1235184" target="_blank" >http://dx.doi.org/10.1080/10641963.2016.1235184</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1080/10641963.2016.1235184" target="_blank" >10.1080/10641963.2016.1235184</a>

Result language

angličtina

Original language name

Renin-angiotensin system blockade alone or combined with ETA receptor blockade: effects on the course of chronic kidney disease in 5/6 nephrectomized Ren-2 transgenic hypertensive rats

Original language description

Early addition of endothelin (ET) type A (ETA) receptor blockade to complex renin–angiotensin system (RAS) blockade has previously been shown to provide better renoprotection against progression of chronic kidney disease (CKD) in Ren-2 transgenic hypertensive rats (TGR) after 5/6 renal ablation (5/6 NX). In this study, we examined if additional protection is provided when ETA blockade is applied in rats with already developed CKD. Methods: For complex RAS inhibition, an angiotensin-converting enzyme inhibitor along with angiotensin II type 1 receptor blocker was used. Alternatively, ETA receptor blocker was added to the RAS blockade. The treatments were initiated 6 weeks after 5/6 NX and the follow-up period was 50 weeks. Results: When applied in established CKD, addition of ETA receptor blockade to the complex RAS blockade brought no further improvement of the survival rate (30% in both groups), surprisingly, aggravated albuminuria (588 ± 47 vs. 245 ± 38 mg/24 h, p < 0.05) did not reduce renal glomerular injury index (1.25 ± 0.29 vs. 1.44 ± 0.26), did not prevent the decrease in creatinine clearance (203 ± 21 vs. 253 ± 17 µl/min/100 g body weight), and did not attenuate cardiac hypertrophy to a greater extent than observed in 5/6 NX TGR treated with complex RAS blockade alone. Conclusions: When applied in the advanced phase of CKD, addition of ETA receptor blockade to the complex RAS blockade brings no further beneficial renoprotective effects on the CKD progression in 5/6 NX TGR, in addition to those seen with RAS blockade alone.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30201 - Cardiac and Cardiovascular systems

Project

<a href="/en/project/NV15-28671A" target="_blank" >NV15-28671A: Pharmacological blockade of both the endothelin system and soluble epoxyde hydrolase as a new aproach to the treatment of hypertensive organ damage</a><br>

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2017

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Clinical and Experimental Hypertension

ISSN

1064-1963

e-ISSN

—

Volume of the periodical

39

Issue of the periodical within the volume

2

Country of publishing house

US - UNITED STATES

Number of pages

13

Pages from-to

183-195

UT code for WoS article

000396749000014

EID of the result in the Scopus database

2-s2.0-84859374582